Literature DB >> 31892786

Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans.

Renata J M Engler1, Emily Brede1, Todd Villines1, Marina N Vernalis1.   

Abstract

Newly recognized as a clinical diagnosis, Lp(a) elevation is a major contributor to cardiovascular disease risk should be considered for patients with advanced premature atherosclerosis on imaging or a family history of premature cardiovascular disease, particularly when there are few traditional risk factors.
Copyright © 2019 Frontline Medical Communications Inc., Parsippany, NJ, USA.

Entities:  

Year:  2019        PMID： 31892786      PMCID： PMC6913584     

Source DB:  PubMed          Journal:  Fed Pract        ISSN： 1078-4497


  143 in total

1.  Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline.

Authors:  John R Downs; Patrick G O'Malley
Journal:  Ann Intern Med       Date:  2015-08-18       Impact factor: 25.391

2.  Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.

Authors:  Fleur M van der Valk; Siroon Bekkering; Jeffrey Kroon; Calvin Yeang; Jan Van den Bossche; Jaap D van Buul; Amir Ravandi; Aart J Nederveen; Hein J Verberne; Corey Scipione; Max Nieuwdorp; Leo A B Joosten; Mihai G Netea; Marlys L Koschinsky; Joseph L Witztum; Sotirios Tsimikas; Niels P Riksen; Erik S G Stroes
Journal:  Circulation       Date:  2016-08-05       Impact factor: 29.690

3.  Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis.

Authors:  Alexander H Nave; Kristin S Lange; Christopher O Leonards; Bob Siegerink; Wolfram Doehner; Ulf Landmesser; Elisabeth Steinhagen-Thiessen; Matthias Endres; Martin Ebinger
Journal:  Atherosclerosis       Date:  2015-08-15       Impact factor: 5.162

4.  Development of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a) by using purified human oxidized lipoprotein(a) autoantibodies as capture antibody.

Authors:  Junjun Wang; Chunni Zhang; Jianbin Gong; Yanfei Zhu; Li Fu; Xiangdong Wang; Ke Li
Journal:  Clin Chim Acta       Date:  2007-07-21       Impact factor: 3.786

5.  Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States.

Authors:  Steve Varvel; Joseph P McConnell; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-09-22       Impact factor: 8.311

6.  Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients.

Authors:  Stephen J Nicholls; Giacomo Ruotolo; H Bryan Brewer; Ming-Dauh Wang; Liping Liu; Mark B Willey; Mark A Deeg; Kathryn A Krueger; Steven E Nissen
Journal:  J Clin Lipidol       Date:  2015-12-18       Impact factor: 4.766

7.  Prevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999-2010.

Authors:  Cheryl D Fryar; Te-Ching Chen; Xianfen Li
Journal:  NCHS Data Brief       Date:  2012-08

8.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

9.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Authors:  Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2018-11-07       Impact factor: 91.245

10.  The Copenhagen City Heart Study (Østerbroundersøgelsen).

Authors:  Yasmine Aguib; Jassim Al Suwaidi
Journal:  Glob Cardiol Sci Pract       Date:  2015-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.